Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation

International Journal of Cancer

Volumn 130, Issue 9, 2012, Pages 2164-2175

  Vynnytska Myronovska, Bozhena ^a,b   Bobak, Yaroslav ^a   Garbe, Yvette ^b   Dittfeld, Claudia ^b   Stasyk, Oleh ^a   Kunz Schughart, Leoni A ^b  

^a INSTITUTE OF CELL BIOLOGY   (Ukraine)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

arginine starvation; canavanine treatment; single dose irradiation; spheroid culture

Indexed keywords

ARGINASE; ARGININE; CANAVANINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL GROWTH; CELL REGROWTH; CELL SURVIVAL; CHEMORADIOTHERAPY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIZATION; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; IRRADIATION; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; SINGLE AMINO ACID ARGININE STARVATION; TUMOR SPHEROID;

APOPTOSIS; ARGININE; CANAVANINE; CELL LINE, TUMOR; CYTOPROTECTION; ENZYME INHIBITORS; HCT116 CELLS; HT29 CELLS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; RADIATION TOLERANCE; SPHEROIDS, CELLULAR;

EID: 84857502470     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26221     Document Type: Article

References (47)

1. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, et al., Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004; 22: 1815-22.
2. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, et al., Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010; 28: 2220-6.
3. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, et al,. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010; 103: 954-60.
4. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, et al., Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23: 7660-8.
5. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA,. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004; 100: 826-33.
6. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA,. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006; 12: 7126-31.
7. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH,. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007; 120: 897-905.
8. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ,. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008; 123: 1950-5.
9. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW,. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010; 126: 2762-72.
10. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC,. Pegylated recombinant human arginase (rhArg-peg5000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67: 309-17.
11. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT,. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther 2009; 8: 3223-33.
12. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid P, Crook T,. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009; 125: 1454-63.
13. Vynnytska BO, Mayevska OM, Kurlishchuk YV, Bobak YP, Stasyk OV,. Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells. Anticancer Drugs 2011; 22: 148-57.
14. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA,. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009; 4: 309-24.
15. Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA,. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010; 4: 375-83.
16. Stasyuk NY, Gayda GZ, Koval'chuk YP, Stasyk OV, Gonchar MV,. Human arginase I from the recombinant yeast Hansenula polymorpha: isolation and characterization of the enzyme. Ukr Biokhim Zh 2010; 82: 53-60.
17. Bobak YP, Vynnytska BO, Kurlishchuk YV, Sibirny AA, Stasyk OV,. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell Biol Int 2010; 4: 1085-9.
18. Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemin F, Plenat F,. Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J Histochem Cytochem 2009; 57: 289-300.
19. Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW,. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 2007; 18: 1373-7.
20. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R,. The use of 3D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004; 9: 273-85.
21. Friedrich J, Ebner R, Kunz-Schughart LA,. Experimental anti-tumor therapy in 3D: spheroidsâ€"old hat or new challenge? Int J Radiat Biol 2007; 83: 849-71.
22. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA,. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
23. Wheatley DN, Kilfeather R, Stitt A, Campbell E,. Integrity and stability of the citrulline-arginine pathway in normal and tumour cell lines. Cancer Lett 2005; 227: 141-52.
24. Wheatley DN,. Controlling cancer by restricting arginine availabilityâ€"arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 2004; 15: 825-33.
25. Scott L, Lamb J, Smith S, Wheatley DN,. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000; 83: 800-10.
26. Bence AK, Crooks PA,. The mechanism of L-canavanine cytotoxicity: arginyl tRNA synthetase as a novel target for anticancer drug discovery. J Enzyme Inhib Med Chem 2003; 18: 383-94.
27. Green MH, Brooks TL, Mendelsohn J, Howell SB,. Antitumor activity of L-canavanine against L1210 murine leukemia. Cancer Res 1980; 40: 535-7.
28. Swaffar DS, Ang CY, Desai PB, Rosenthal GA,. Inhibition of the growth of human pancreatic cancer cells by the arginine antimetabolite L-canavanine. Cancer Res 1994; 54: 6045-8.
29. Swaffar DS, Ang CY,. Growth inhibitory effect of L-canavanine against MIA PaCa-2 pancreatic cancer cells is not due to conversion to its toxic metabolite canaline. Anticancer Drugs 1999; 10: 113-8.
30. Ding Y, Matsukawa Y, OhtaniFujita N, Kato D, Dao S, Fujii T, Naito Y, Yoshikawa T, Sakai T, Rosenthal GA,. Growth inhibition of A549 human lung adenocarcinoma cells by L-canavanine is associated with p21/WAF1 induction. Jpn J Cancer Res 1999; 90: 69-74.
31. Jang MH, Jun DY, Rue SW, Han K, Park W, Kim YH,. Arginine antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xL. Biochem Biophys Res Commun 2002; 295: 283-8.
32. Thomas DA, Rosenthal GA, Gold DV, Dickey K,. Growth inhibition of a rat colon tumor by L-canavanine. Cancer Res 1986; 46: 2898-903.
33. Worthen DR, Chien L, Tsuboi CP, Mu XY, Bartik MM, Crooks PA,. L-Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human tumor cell lines. Cancer Lett 1998; 132: 229-39.
34. Jackson MJ, O'Brien WE, Beaudet AL,. Arginine-mediated regulation of an argininosuccinate synthetase minigene in normal and canavanine-resistant human cells. Mol Cell Biol 1986; 6: 2257-61.
35. Su TS, Beaudet AL, O'Brien WE,. Increased translatable messenger ribonucleic acid for argininosuccinate synthetase in canavanine-resistant human cells. Biochemistry 1981; 20: 2956-60.
36. Morris SM, Jr,. Arginine: beyond protein. Am J Clin Nutr 2006; 83: 508-12.
37. Park H, Lee JB, Shim YJ, Shin YJ, Jeong SY, Oh J, Park GH, Lee KH, Min BH,. Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins. Mol Cells 2008; 25: 305-11.
38. Dang CV,. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc 2007; 4: 35-53.
39. Mason SD, Rundqvist H, Papandreou I, Duh R, McNulty WJ, Howlett RA, Olfert IM, Sundberg CJ, Denko NC, Poellinger L, Johnson RS,. HIF-1alpha in endurance training: suppression of oxidative metabolism. Am J Physiol Regul Integr Comp Physiol 2007; 293: 2059-69.
40. Warters RL, Newton GL, Olive PL, Fahey RC,. Radioprotection of human cell nuclear DNA by polyamines: radiosensitivity of chromatin is influenced by tightly bound spermine. Radiat Res 1999; 151: 354-62.
41. Arundel CM, Nishioka K, Tofilon PJ,. Effects of alpha- difluoromethylornithine-induced polyamine depletion on the radiosensitivity of a human colon carcinoma cell line. Radiat Res 1988; 114: 634-40.
42. Snyder RD, Schroeder KK,. Radiosensitivity of polyamine-depleted HeLa cells and modulation by the aminothiol WR-1065. Radiat Res 1994; 137: 67-75.
43. Policastro L, Duran H, Henry Y, Molinari B, Favaudon V,. Selective radiosensitization by nitric oxide in tumor cell lines. Cancer Lett 2007; 248: 123-30.
44. Griffin RJ, Makepeace CM, Hur WJ, Song CW,. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys 1996; 36: 377-83.
45. Agani FH, Puchowicz M, Chavez JC, Pichiule P, LaManna J,. Role of nitric oxide in the regulation of HIF-1α expression during hypoxia. Am J Physiol Cell Physiol 2002; 283: 178-86.
46. Green MH, Ward JF,. Enhancement of human tumor cell killing by L-canavanine in combination with gamma-radiation. Cancer Res 1983; 43: 4180-2.
47. Bence AK, Adams VR, Crooks PA,. L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. Mol Cell Biochem 2003; 244: 37-43.